Sector Watch: Healthcare - Mar 29 2019
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $111.80 +2.34 2.14% | XBI: $90.54 +1.65 1.86% | Updated Mar 29, 2019 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| GLPG Galapagos NV $5.9B |
117.78+21.65 1.5 M 19.0x |
23% | ||
| AVEO AVEO Pharmaceuticals $114.0M |
0.82+0.13 14.8 M 2.8x |
18% | ||
| VKTX Viking Therapeutics $715.5M |
9.94+1.43 14.8 M 4.6x |
17% | ||
| ADMA ADMA Biologics Inc $175.7M |
3.79+0.50 1.4 M 2.8x |
15% | ||
| AEZS52WH AEterna Zentaris $76.5M |
4.65+0.52 785.2 K 3.5x |
13% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| VRML Vermillion $86.7M |
1.15-0.14 318.6 K |
-11% | ||
| CCM Concord Medical Services Holdings $236.4M |
2.80-0.31 2.2 K |
-10% | ||
| CHMA Chiasma $127.2M |
5.20-0.56 1.1 M 7.6x |
-10% | ||
| CASI CASI Pharmaceuticals $268.6M |
2.87-0.30 331.0 K 1.6x |
-9% | ||
| RYTM Rhythm Pharmaceuticals $943.6M |
27.41-2.44 176.1 K 2.2x |
-8% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN [globenewswire.com]Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock [globenewswire.com]
Chiasma Announces Proposed Offering of Common Stock [globenewswire.com]
Vermillion Reports Fourth Quarter and Year-End 2018 Financial Results [globenewswire.com]
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients | Business Wire [businesswire.com]
Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC [globenewswire.com]
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, AVEO Pharmaceuticals, Stamps.com, and Syneos and Encourages Investors to Contact the Firm [globenewswire.com]
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development [globenewswire.com]
CLASS ACTION UPDATE for UXIN, AVEO, AMRN and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [globenewswire.com]
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors to Contact the Firm [globenewswire.com]
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results [globenewswire.com]
AVEO: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against AVEO Pharmaceuticals Inc.? AVEO - GlobeNewswire [globenewswire.com]
Chiasma Announces Three Poster Presentations at ENDO 2019 [globenewswire.com]
CLASS ACTION UPDATE for AVEO, STMP, AMR and MBT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [globenewswire.com]
Galapagos increases share capital through warrant exercises [globenewswire.com]
HIIQ, AVEO & CVS Bronstein, Gewirtz & Grossman, LLC Class Action Reminder [globenewswire.com]
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, ASTE, VALE and AVEO [globenewswire.com]
Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019 [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
